CG Oncology Inc (CGON)

CG Oncology Inc (CGON) Healthcare & Pipeline Overview

CG Oncology Inc. is a clinical-stage biopharmaceutical company specializing in bladder-sparing therapeutics, with its lead candidate, cretostimogene, targeting high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company aims to address the unmet needs of patients unresponsive to the current standard-of-care, BCG therapy, in the biotechnology sector.

What Is the Investment Thesis for CGON?

CG Oncology presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, cretostimogene, targeting a significant unmet need in high-risk NMIBC patients unresponsive to BCG therapy. With a market capitalization of $6.11B, the company's valuation hinges on the successful clinical development and commercialization of cretostimogene. Key value drivers include positive clinical trial outcomes, regulatory approvals, and market penetration in the NMIBC treatment landscape. Upcoming clinical trial data releases will serve as major catalysts, while potential setbacks in clinical development or regulatory hurdles represent key risk factors. The company's negative profit margin of -2495.4% underscores its reliance on future product revenue and strategic partnerships to achieve profitability.

Based on FMP financials and quantitative analysis

CGON Key Highlights

• Market Cap of $6.11B reflects investor confidence in CG Oncology's pipeline and potential market opportunity.
• Profit Margin of -2495.4% indicates the company is in the clinical development stage and not yet generating significant revenue.
• Gross Margin of -50.0% suggests high costs associated with research and development activities.
• Beta of 0.70 indicates lower volatility compared to the overall market, suggesting a relatively stable investment.
• Lead product candidate, cretostimogene, targets a significant unmet need in high-risk NMIBC patients unresponsive to BCG therapy, offering a potential backbone bladder-sparing therapeutic.

Who Are CGON's Competitors?

CGON is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CGON's Key Strengths?

• Novel therapeutic approach with cretostimogene.
• Focus on a specific unmet need in bladder cancer treatment.
• Experienced management team with expertise in drug development.
• Strong intellectual property protection for cretostimogene.

What Are CGON's Weaknesses?

• Clinical-stage company with no currently approved products.
• High dependence on the success of cretostimogene.
• Negative profit margin and reliance on future funding.
• Limited commercial infrastructure and market presence.

What Could Drive CGON Stock Higher?

• Release of Phase 3 clinical trial data for cretostimogene in high-risk NMIBC patients unresponsive to BCG therapy.
• Potential regulatory submission for cretostimogene to health authorities, such as the FDA.
• Enrollment and progress in ongoing clinical trials for cretostimogene.
• Expansion of strategic partnerships and collaborations to support development and commercialization.

What Are the Key Risks for CGON?

• Negative return on equity (-23.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in the development of cretostimogene.
• Regulatory hurdles and delays in obtaining marketing approval for cretostimogene.
• Competition from existing and emerging therapies in the bladder cancer treatment landscape.
• Dependence on future funding to support research and development activities.
• Patent challenges or loss of exclusivity for cretostimogene.

What Are the Growth Opportunities for CGON?

• Expansion into Additional Bladder Cancer Subtypes: CG Oncology has the opportunity to expand the application of cretostimogene beyond high-risk NMIBC to other bladder cancer subtypes, such as muscle-invasive bladder cancer (MIBC). This expansion could significantly increase the addressable patient population and market potential for cretostimogene. The market for MIBC treatments is substantial, with ongoing research and development efforts focused on improving survival rates and quality of life. Timeline for expansion is dependent on clinical trial results, but could be initiated within the next 3-5 years.
• Strategic Partnerships and Collaborations: CG Oncology can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of cretostimogene. Collaborations could provide access to additional resources, expertise, and distribution networks, enhancing the company's ability to reach a broader patient population. The timeline for establishing partnerships is ongoing, with potential deals being evaluated based on strategic fit and financial terms. This could lead to increased market penetration and revenue growth.
• Geographic Expansion into International Markets: CG Oncology has the potential to expand its market reach beyond the United States to international markets, such as Europe and Asia. These markets represent significant growth opportunities, particularly in regions with high prevalence of bladder cancer and limited access to advanced therapies. The timeline for international expansion is contingent on regulatory approvals and market access strategies, but could be initiated within the next 3-5 years. This would require establishing local partnerships and navigating regulatory pathways.
• Development of Companion Diagnostics: CG Oncology could develop companion diagnostics to identify patients who are most likely to respond to cretostimogene. This would enable more targeted treatment and improve patient outcomes, while also enhancing the cost-effectiveness of the therapy. The market for companion diagnostics is growing rapidly, driven by the increasing adoption of personalized medicine. The timeline for developing companion diagnostics is dependent on biomarker discovery and validation, but could be initiated within the next 2-3 years.
• Combination Therapies with Other Immunotherapies: CG Oncology can explore the potential of combining cretostimogene with other immunotherapies, such as checkpoint inhibitors, to enhance the anti-tumor response. Combination therapies have shown promising results in various cancer types, and could potentially improve the efficacy of cretostimogene in bladder cancer. The timeline for combination therapy development is dependent on preclinical and clinical trial results, but could be initiated within the next 1-2 years. This could lead to synergistic effects and improved patient outcomes.

What Opportunities Does CGON Have?

• Expansion into additional bladder cancer subtypes.
• Strategic partnerships with larger pharmaceutical companies.
• Geographic expansion into international markets.
• Development of companion diagnostics to personalize treatment.

What Threats Does CGON Face?

• Clinical trial failures or delays.
• Regulatory hurdles and delays in approval.
• Competition from existing and emerging therapies.
• Patent challenges or loss of exclusivity.

What Are CGON's Competitive Advantages?

• Proprietary Technology: CG Oncology's cretostimogene is a novel oncolytic immunotherapy with a unique mechanism of action.
• Clinical Stage: Being in clinical development provides a barrier to entry, as competitors would need to invest significant time and resources to catch up.
• Patent Protection: Patents covering cretostimogene provide exclusivity and prevent competitors from developing similar therapies.
• Expertise: CG Oncology's team has deep expertise in bladder cancer and immunotherapy.

What Does CGON Do?

CG Oncology Inc., headquartered in Irvine, California, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative bladder-sparing therapeutics for bladder cancer patients. The company's primary focus is on addressing the unmet needs of individuals suffering from Non-Muscle Invasive Bladder Cancer (NMIBC), particularly those who have become unresponsive to the current standard treatment, Bacillus Calmette Guerin (BCG) therapy. CG Oncology's lead product candidate, cretostimogene, is currently undergoing clinical development as a potential backbone therapy for this patient population. The company's approach centers around leveraging innovative scientific advancements to create targeted therapies that can improve patient outcomes while preserving bladder function. By focusing on bladder-sparing treatments, CG Oncology aims to enhance the quality of life for patients who often face radical cystectomy (bladder removal) as a result of their condition. CG Oncology is committed to advancing the field of bladder cancer treatment through rigorous research, clinical trials, and strategic partnerships. Their ultimate goal is to establish cretostimogene as a new standard of care for high-risk NMIBC, providing a more effective and less invasive treatment option for patients in need. CG Oncology manages 113 employees.

What Products and Services Does CGON Offer?

• Develop bladder-sparing therapeutics for bladder cancer patients.
• Focus on Non-Muscle Invasive Bladder Cancer (NMIBC) treatment.
• Target patients unresponsive to Bacillus Calmette Guerin (BCG) therapy.
• Conduct clinical trials to evaluate the safety and efficacy of cretostimogene.
• Seek regulatory approvals for cretostimogene from health authorities.
• Commercialize and market cretostimogene upon regulatory approval.
• Explore strategic partnerships to expand market reach and accelerate development.

How Does CGON Make Money?

• Develop and patent novel bladder cancer therapeutics.
• Conduct clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved therapies through direct sales or partnerships.

What Industry Does CGON Operate In?

CG Oncology operates within the biotechnology industry, specifically targeting the bladder cancer therapeutics market. The bladder cancer treatment landscape is characterized by a significant unmet need for effective and less invasive therapies, particularly for patients with high-risk NMIBC who have failed BCG therapy. The company's focus on bladder-sparing treatments aligns with the growing trend towards personalized medicine and improved patient quality of life. Competitors in this space include CELC: Celcuity Inc., CNTA: Centessa Pharmaceuticals plc, LEGN: Legend Biotech Corporation, APGE: Apogee Therapeutics, Inc., and XENE: Xenon Pharmaceuticals Inc., each pursuing different approaches to cancer treatment.

Who Are CGON's Key Customers?

• Patients diagnosed with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC).
• Oncologists and urologists specializing in bladder cancer treatment.
• Hospitals and cancer centers providing cancer care.
• Healthcare payers, including insurance companies and government healthcare programs.

F-Score 3/9Financial Health

CG Oncology Inc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 85.68 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -23%Key Financial Metrics

Return on equity for CG Oncology Inc stands at -23.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 31.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.1%, the inverse of the P/E and a quick read on earnings relative to price.

CG Oncology Inc (CGON) Valuation Context

Valued at $6.11B, CGON is classified as a mid-cap stock. Relative to its peer group, CGON's quantitative score of 24/100 is below the peer average of 52/100.

FY2026 estForward Outlook

Wall Street analysts project CG Oncology Inc revenue of about $11.1M for fiscal 2026, with EPS near $-2.73. The estimate reflects 11 contributing analysts.

Net buyingInsider Activity

Over the past six months, CG Oncology Inc insiders filed 30 SEC Form 4 transactions — 12 sales and 18 purchases. On net that is roughly 628K shares acquired (about $41.8M) — insiders putting money in tends to read as conviction.

CGON Financials

CGON Latest News

CGON Analyst Consensus

CGON MoonshotScore

What Investors Ask About CG Oncology Inc (CGON) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources